Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600958 | 0.90 | FFAR4 (0.35) | TACR1CYP2D6TSHR | |
| SCHEMBL1601502 | 0.89 | TACR1 (0.45) | TACR1GPR119ENPP2MAPTEPHX2 | |
| SCHEMBL1599597 | 0.86 | TACR1 (0.46) | TACR1GPR119ENPP2MAPTEPHX2 | |
| SCHEMBL1600479 | 0.85 | TACR1 (0.46) | TACR1GPR119ENPP2MAPTEPHX2 | |
| SCHEMBL1600514 | 0.81 | IDO1 (0.33) | TACR1 | |
| SCHEMBL1601333 | 0.78 | TACR1 (0.35) | TACR1TSHR | |
| SCHEMBL1600861 | 0.74 | TACR1 (0.43) | TACR1GPR119ENPP2CYP2D6TSHR | |
| SCHEMBL4740617 | 0.73 | FFAR4 (0.42) | TACR1CYP2D6TSHR | |
| SCHEMBL1600956 | 0.72 | FFAR4 (0.38) | TACR1CYP2D6TSHR | |
| SCHEMBL1600421 | 0.72 | MEN1 (0.40) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | TACR1 2334/4885GPR119 198/4885ENPP2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.